![]()
柔红霉素用途
Daunorubicin(RP13057)能抑制DNA和RNA合成，对DNA合成的Ki为0.02 μM。
1、产品物理参数：
|
常用名
|
柔红霉素
|
英文名
|
Daunorubicin
|
|
CAS号
|
20830-81-3
|
分子量
|
527.520
|
|
密度
|
1.6±0.1 g/cm3
|
沸点
|
770.0±60.0 °C at 760 mmHg
|
|
分子式
|
C27H29NO10
|
熔点
|
155ºC
|
|
闪点
|
419.5±32.9 °C
|
|
|
2、技术资料：
|
体外研究
|
Molt-4细胞中柔红霉素（Dnr）的平均IC50值为0.04μM。柔红霉素属于蒽环霉素，一组细胞毒性化学治-疗剂。蒽环霉素的细胞毒性作用是由DNA插入和通过抑制拓扑异构酶II以及产生活性氧来干扰DNA转录和复制的能力引起的[2]柔红霉素抑制HeLa细胞中DNA和RNA合成的浓度范围0.2至2μM。对于人胰腺细胞系L3.6中的柔红霉素（Dnr），IC50值为0.4μM[3]。
|
|
体内研究
|
与对照组相比，柔红霉素组（3mg / kg，iv）中尿蛋白排泄，血清肌酐和血尿素氮（BUN）水平显着增加。与对照组相比，柔红霉素（DNR）的施用导致肾组织中丙二醛（MDA）水平显着增加[4]。
|
3、柔红霉素物理化学性质
|
密度
|
1.6±0.1 g/cm3
|
|
沸点
|
770.0±60.0 °C at 760 mmHg
|
|
熔点
|
155ºC
|
|
分子式
|
C27H29NO10
|
|
分子量
|
527.520
|
|
闪点
|
419.5±32.9 °C
|
|
精-确质量
|
527.179138
|
|
PSA
|
185.84000
|
|
LogP
|
2.92
|
|
外观性状
|
橙色-红色粉末
|
|
蒸汽压
|
0.0±2.8 mmHg at 25°C
|
|
折射率
|
1.692
|
|
储存条件
|
放入紧密的贮藏器内
|
|
稳定性
|
避免接触强氧化物
|
|
分子结构
|
1、 摩尔折射率：129.98
2、 摩尔体积(m3/mol)：339.4
3、 等张比容(90.2K)：1037.9
4、 表面张力(dyne/cm)：87.4
5、 极化率(10-24cm3)：51.52
|
4、柔红霉素英文别名
|
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
|
|
DAUNOMYCIN
|
|
daunamycin
|
|
5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-
|
|
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
|
|
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
|
|
daunoxome
|
|
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
|
|
fi6339
|
|
5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-
|
|
cerubidin
|
|
rubomycinc
|
|
5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-
|
|
Daunorubicin
|
|
(8S,10S)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
|
|
(8S,10S)-8-Acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracen-5,12-dion
|
|
(8S,10S)-8-acétyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-méthyltétrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-1-méthoxy-7,8,9,10-tétrahydrotétracène-5,12-dione
|
|
EINECS 245-723-4
|
|
(8S,10S)-8-acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
|
|
Cerubidine(R)
|
|
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
|
|
(8S,10S)-8-Acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydro-5,12-tetracenedione
|
|
daunorubicinum [INN_la]
|
|
RUBIDOMYCIN
|
